Seaport Therapeutics
Open
$15.79
Prev. Close
$15.87
High
$15.79
Low
$15.75
Market Snapshot
$793.46M
Seaport Therapeutics Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Boston, Massachusetts. The company went IPO on 2026-05-01. Seaport Therapeutics, Inc. is a clinical-stage therapeutics company. The firm is focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Its product candidate, GlyphAlloTM (SPT-300 or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically validated in third-party trials for the treatment of postpartum depression. GlyphAgoTM (SPT-320 or Glyph Agomelatine), is a novel, Glyphed oral prodrug of agomelatine, a clinically validated anxiolytic and antidepressant that is approved for the treatment of generalized anxiety disorder. The company is also advancing Glyph2BLSDTM (SPT-348 or Glyph 2-bromo-LSD), a novel, Glyphed oral prodrug of the non-hallucinogenic LSD analog 2-bromo-LSD, in preclinical studies for depressive disorders. GlyphAllo is designed to overcome the bioavailability limitations of allopregnanolone and be durable in MDD.
Seaport Therapeutics Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Boston, Massachusetts. The company went IPO on 2026-05-01. Seaport Therapeutics, Inc. is a clinical-stage therapeutics company. The firm is focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Its product candidate, GlyphAlloTM (SPT-300 or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically validated in third-party trials for the treatment of postpartum depression. GlyphAgoTM (SPT-320 or Glyph Agomelatine), is a novel, Glyphed oral prodrug of agomelatine, a clinically validated anxiolytic and antidepressant that is approved for the treatment of generalized anxiety disorder. The company is also advancing Glyph2BLSDTM (SPT-348 or Glyph 2-bromo-LSD), a novel, Glyphed oral prodrug of the non-hallucinogenic LSD analog 2-bromo-LSD, in preclinical studies for depressive disorders. GlyphAllo is designed to overcome the bioavailability limitations of allopregnanolone and be durable in MDD.
Recently from Cashu
Couldn't load Cashu news
Something went wrong. Try refreshing the page.